Rodman & Renshaw initiated coverage of FibroBiologics (FBLG) with a Buy rating and $12 price target
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics files patent application for cell-based therapeutic
- FibroBiologics files patent application on reduction of clots related to IBMIR
- FibroBiologics Reports Q3 2024 Financial Results
- Alphabet upgraded, Boeing downgraded: Wall Street’s top analyst calls
- FibroBiologics initiated with a Buy at H.C. Wainwright